

Claims

1. An enzymatic RNA molecule which cleaves *rel A* mRNA .
- 5 2. An enzymatic RNA molecule of claim 1, the binding arms of which contain sequences complementary to the sequences defined in Table II.
3. The enzymatic RNA molecule of claim 1, the binding arms of which contain sequences complementary to the sequences defined in any one of Tables III, and IV - VII
- 10 4. The enzymatic RNA molecule of claims 1, 2, or 3, wherein said RNA molecule is in a hammerhead motif.
5. The enzymatic RNA molecule of claim 1, 2, or 3, wherein said RNA molecule is in a hairpin, hepatitis delta virus, group 1 intron, VS RNA or RNaseP RNA motif.
- 15 6. The enzymatic RNA molecule of claim 6, wherein said ribozyme comprises between 12 and 100 bases complementary to said mRNA.
7. The enzymatic RNA molecule of claim 6, wherein said ribozyme comprises between 14 and 24 bases complementary to said mRNA.
- 20 8. Enzymatic RNA molecule consisting essentially of any sequence selected from the group of those shown in Tables IV, V, VI, and VII.
9. A mammalian cell including an enzymatic RNA molecule of claims 1, 2, or 3.
- 25 10. The cell of claim 8, wherein said cell is a human cell.
11. An expression vector including nucleic acid encoding an enzymatic RNA molecule or multiple enzymatic molecules of claims 1, 2, or 3 in a manner which allows expression of that enzymatic RNA molecule(s) within a mammalian cell.

12. A mammalian cell including an expression vector of claim 11.
13. The cell of claim 13, wherein said cell is a human cell.
14. A method for treatment of a condition related to the level of NF- κ B activity by administering to a patient an enzymatic nucleic acid molecule of claims 1, 2, or 3,
5
15. A method for treatment of a condition related to the level of NF- κ B activity by administering to a patient an expression vector of claim 11.
16. The method of claims 14 or 15, wherein said patient is a human.
- 10 17. The method of claim 14 wherein said condition is selected from the group consisting of restenosis, rheumatoid arthritis, asthma, inflammatory or autoimmune disorders, and transplant rejection.
- 15 18. The method of claim 15 wherein said condition is selected from the group consisting of restenosis, rheumatoid arthritis, asthma, inflammatory or autoimmune disorders, and transplant rejection.